MAP2K7 and malignant peripheral nerve sheath tumor: Finally, it has been described that loss of PRC2 confers sensitivity to BRD4 inhibition in MPNST.7 Several combined therapies considering the BRD4 inhibitor JQ1 and other MPNST targets, such as MEK,7 and mTOR37 have been proposed.